CompletedPhase 2

Olanzapine in the Treatment of Patients With Anorexia Nervosa

Canada34 participantsStarted 2000-09

Plain-language summary

The purpose of the study is to evaluate the efficacy of an anti-psychotic medication, Olanzapine, in achieving desired weight gain in patients identified as having Anorexia Nervosa, either restricting or binge/purge subtype. The study will also evaluate the possible beneficial effects of Olanzapine in reducing the severity of the obsessive and/or anxiety symptoms associated with this disorder.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * those who meet DSM IV criteria of Anorexia Nervosa- either restricting or binge/purge subtype Exclusion Criteria: * patients who are actively self destructive and/or suicidal * patients whose medical status is seriously compromised * patients whose eating disorder is superimposed on a major psychiatric disorder such as schizophrenia, major affective disorders, dissociative disorder or an active substance abuse disorder.

What they're measuring

Body Mass Index (BMI) (kg/m^2)

Timeframe: Baseline (week 2) and post-treatment (week 13)

Trial details

NCT IDNCT00260962

SponsorOttawa Hospital Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2006-07

Results submitted2017-01-26

View on ClinicalTrials.gov More Anorexia Nervosa trials